Agenus Inc. (NASDAQ:AGEN) Receives $14.50 Consensus PT from Analysts

Agenus Inc. (NASDAQ:AGEN) has been assigned an average rating of “Hold” from the five analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have given a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $14.50.

Several research firms have commented on AGEN. Zacks Research upgraded shares of Agenus to a “hold” rating in a report on Tuesday, August 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Agenus in a research note on Wednesday, November 19th. Wall Street Zen lowered shares of Agenus from a “buy” rating to a “hold” rating in a research note on Sunday, August 17th. Finally, HC Wainwright reissued a “buy” rating on shares of Agenus in a report on Monday, October 20th.

Hedge Funds Weigh In On Agenus

Large investors have recently made changes to their positions in the company. Traynor Capital Management Inc. bought a new stake in Agenus in the 3rd quarter valued at $50,000. Catalyst Funds Management Pty Ltd bought a new position in Agenus during the 2nd quarter worth $50,000. Squarepoint Ops LLC acquired a new stake in shares of Agenus during the third quarter worth $54,000. Jump Financial LLC bought a new stake in shares of Agenus in the second quarter valued at about $55,000. Finally, Acadian Asset Management LLC bought a new stake in shares of Agenus in the first quarter valued at about $58,000. Institutional investors own 61.46% of the company’s stock.

Agenus Stock Up 1.7%

NASDAQ:AGEN opened at $4.29 on Friday. Agenus has a 12-month low of $1.38 and a 12-month high of $7.34. The firm has a market capitalization of $145.89 million, a price-to-earnings ratio of -0.60 and a beta of 1.43. The stock’s 50 day moving average price is $4.14 and its two-hundred day moving average price is $4.58.

Agenus (NASDAQ:AGEN) last issued its earnings results on Monday, November 10th. The biotechnology company reported $1.94 EPS for the quarter, missing the consensus estimate of $2.63 by ($0.69). The firm had revenue of $30.24 million during the quarter, compared to the consensus estimate of $80.39 million. Equities research analysts expect that Agenus will post -12.55 EPS for the current year.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.